IBEX

Grifols becomes second largest shareholder of Chinese Shanghai RAAS

Grifols Offers Hope Of A Treatment For Alzheimer

On Friday Grifols presented the results of its AMBAR (Alzheimer Management by Albumin Replacement) (phase IIb/III) study in Barcelona. AMBAR is an innovative possible treatment based on the therapeutic properties of plasma which has shown, statistically significantly, its effectiveness in slowing the progression Alzheimer in moderately affected patients.



Bankinter's profits increased by 7% in the first nine months of the year

Bankinter Lists At The Most Demanding PER In Spanish Banking Sector

Bankinter has been the first Spanish bank to publish its results. The bank´s shares have risen a modest 0.11% despite the good evolution of its business in the first nine months of the year. In this period profits increased by 7%, its ROE increased to 13.0 and its non- performing assets improved to 3.2%.





In Q3 Repsol Reduces Production By 4.3% To 691,000 Barrels Per Day

According to data provided to the regulator (CNMV) by the company, Repsol´s oil production amounted 691,000 barrels per day in the third quarter of the year, a reduction of 4.3% compared to the previous quarter and practically in line with the 693,000 barrels per day of the same quarter last year.



Acerinox exposure to the US amounts to around 45% of its sales

Acerinox Strong Points Against Trade Environment: Geographical Distribution And Financial Solidity

Acerinox recently celebrated its Capital Markets Day, in which it confirmed its strategy based geographical diversification of its plants (distributed over 4 continents), a policy of differential investment, the control of costs and strengthening its balance sheet, with a special stress on the generation of cash. Its exposure to the US, where the fundamentals remain solid, amounts to around 45% of its sales.


Grifols Defends Itself: US Demand Will Remain Solid

Last week Grifols received a negative recommendation from the global broker UBS, referring to the potential negative impact the commercialisation of a new alternative treatment for autoimmune diseases could have on its sales of intravenous immunoglobin.